Highlights
- Clover Corporation delivered FY26 Revenue growth of 13 per cent to AU$97.4 million, with net profit after tax increasing materially on the prior year.
- Demand for the company's microencapsulated ARA (arachidonic acid, omega-6) powder strengthened in the second half of FY26, contributing to revenue Diversification beyond the constrained infant formula market.
- Gross Margin improvement continued, driven by higher-value products from the company's R&D programme and improved Manufacturing performance at Melody Dairies.
- The board declared a final Dividend for FY26, and the company is evaluating additional spray drying capacity to support CholineXcel production — a core growth opportunity expected to contribute meaningfully from FY28.
Clover Corporation Limited (ASX:CLV) addressed shareholders at its Annual General Meeting with a report of continued progress in FY26, with revenue growing to AU$97.4 million and net profit after tax improving materially on the prior year. The company produces microencapsulated nutritional powders used in infant formula, supplements, and functional food products, and has been expanding its product mix to reduce dependence on the constrained global infant formula market.
Revenue Growth and Product Mix Diversification
Clover's FY26 performance benefited from several converging factors: market Demand for its encapsulated powders, a continuing shift toward higher-value products from its R&D programme, and improved manufacturing output from Melody Dairies, its New Zealand-based manufacturing operation. The Ecuador oil Facility integration continued to progress, contributing to the operational improvements in the period.
While global infant formula markets continue to face structural headwinds from declining birth rates in key markets, Clover's revenue in the second half of FY26 was supported by stronger demand for its microencapsulated ARA powder — an omega-6 fatty acid used in infant and adult nutrition products. The company has also seen its revenue diversification strategy gain traction, with customers catering to older population segments showing increased interest in what management described as clean-label, science-backed nutrition products. The company's distribution strategy is being developed to deepen customer relationships and broaden sales channels beyond its traditional infant formula customer base.
CholineXcel and Future Growth
CholineXcel, Clover's proprietary encapsulated choline product, is described by management as a core growth opportunity that will provide a solid foundation for sustainable revenue growth from FY28 and beyond. Securing additional spray drying capacity is identified as an essential prerequisite for realising this opportunity at scale, and management is evaluating several options. Choline is a conditionally essential nutrient with established roles in brain development and function, with applications in both infant nutrition and adult health supplements.
The company's Development and Innovation Committee, established in the prior calendar year, is actively refining and prioritising the product development pipeline. The committee includes external scientific advisers with relevant academic and industry credentials, providing independent expert input alongside Clover's internal team. The company also has an ongoing investigation into the development of a proprietary range of science-backed nutraceutical products using its encapsulated powders as a platform, which management regards as an additional avenue for future growth.
Key Insights
Clover Corporation enters FY27 with a momentum of continued growth, confirmed by management's indication that the demand growth experienced in FY26 has continued into the first half of FY27 and should result in a material improvement in revenue. The company's ability to maintain and improve gross margins through product mix and manufacturing efficiency is a key driver of profitability Leverage as revenues grow. The CholineXcel capacity question is the principal operational dependency on the medium-term growth plan, and resolution of that manufacturing constraint through the Options under evaluation will be a meaningful milestone for investors monitoring the story.
_11_17_2026_11_03_19_596426.jpg)





Please wait processing your request...